NextCure(NXTC) - 2024 Q4 - Annual Results

Financial Performance - Full year 2024 net loss was $55.7 million, a decrease from a net loss of$62.7 million in 2023, representing a reduction of approximately 11%[10] - Loss from operations for 2024 was $59.7 million, compared to$67.6 million in 2023, indicating an improvement of approximately 11%[13] - General and administrative expenses decreased to $15.7 million in 2024 from$19.7 million in 2023, a reduction of about 20%[10] - Research and development expenses for 2024 were $41.5 million, down from$47.9 million in 2023, reflecting a decrease of about 13%[10] Cash and Assets - Cash, cash equivalents, and marketable securities as of December 31, 2024, were $68.6 million, down from$108.3 million as of December 31, 2023, a decrease of approximately 36.7%[10] - Total assets as of December 31, 2024, were $80.9 million, down from$128.0 million as of December 31, 2023[15] Clinical Development - The company completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in February 2025 and plans to initiate backfill cohorts in the second half of 2025[6] - The U.S. FDA accepted an Investigational New Drug (IND) application for LNCB74 in December 2024, with the first patient dosed in January 2025[7] Future Plans - The company aims to secure financial support for preclinical programs NC181 and NC605, potentially leading to IND filings within 12 to 18 months[10] - The company expects current financial resources to fund operations into the second half of 2026[6]